Evaluation of Pharmacokinetics and Tolerability of Esflurbiprofen Topical System Under Heat, Occlusion, and Exercise Conditions in Healthy Volunteers

The primary objective of this study is to evaluate the effect of **moderate heat**, **occlusion**, and **moderate exercise** on the pharmacokinetics and tolerability of the **Esflurbiprofen Topical System** in healthy volunteers. This investigation is clinically relevant as it aims to understand how external factors such as temperature, skin coverage, and physical activity can influence the absorption and systemic exposure of the drug, which is crucial for optimizing its therapeutic efficacy and safety profile. The study does not include any secondary objectives.

The clinical trial involves a **bioavailability trial with healthy volunteers**, with no specific therapeutic indication being studied. The study population includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial does not specify the total number of participants, as the sponsor has not provided this information. Participants are selected from a non-vulnerable population, indicating that they are generally in good health. There are no specific lifestyle considerations such as diet, physical activity, or habits mentioned for this trial. Key inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is designed as a **randomized**, four-way change-over study to assess the impact of moderate heat, occlusion, and moderate exercise on the pharmacokinetics and tolerability of the Esflurbiprofen topical system in healthy volunteers. This **bioavailability trial** does not study a therapeutic indication and is conducted in a controlled environment to ensure the reliability of the results. The trial is categorized as a Phase 3 study, indicating its advanced stage in the clinical research process. The estimated recruitment start date is February 1, 2025, with an anticipated end date of April 30, 2025, making the overall trial duration approximately three months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a comprehensive assessment to ensure that only suitable candidates are enrolled. Following successful screening, participants will be randomized into different study arms. Throughout the trial, follow-up visits will be scheduled to monitor the participants' response to the intervention and to collect necessary data on pharmacokinetics and tolerability. These visits are crucial for maintaining the integrity of the study and ensuring participant safety. The trial will conclude with an end-of-study visit, where final assessments will be conducted, and participants will be debriefed on their involvement in the study.

The expected length of participant involvement is contingent upon the completion of all scheduled visits and adherence to the study protocol. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with study requirements, or withdraw consent. The study is structured to minimize risks and maximize the collection of high-quality data, contributing to the understanding of the Esflurbiprofen topical system's pharmacokinetics under various conditions.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the experimental medication's maximum daily dose, maximum total dose, or maximum treatment period. Furthermore, there is no information on whether the formulation is pediatric or if the product is classified as an orphan drug.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on February 1, 2025, with an estimated end date of April 30, 2025. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The efficacy parameters will be evaluated at various timepoints throughout the study, utilizing appropriate tools and instruments to ensure accurate and reliable measurements. The analysis will be conducted in accordance with the trial's protocol to determine the treatment's effectiveness in the specified medical condition.